Videos

Dr Graff discusses how to operationalize bispecific antibody (BsAb) therapy in community practices by summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.

Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

Joshua K. Sabari, MD, discusses the efficacy outcomes from the Ideate-Lung02 trial, noting the 52.4% ORR, 5.9-month median DOR, and 12.2-month OS and emphasizing that a 12-month OS is clinically meaningful for this patient population following a median of 2 prior lines of therapy.

Saeed Sadeghi, MD, explores the future treatment landscape for anemia in lower-risk myelodysplastic syndromes (LR-MDS), discussing the impact of emerging therapies on erythropoietin-stimulating agents (ESAs), identifying unmet needs in anemia management, and sharing clinical insights for community oncologists.

Joshua K. Sabari, MD, discusses whether individual B7-H3 analysis is available at his institution, noting that, if it is, he obtains IHC for both PD-L1 and B7-H3 expression levels in all patients with SCLC. If B7-H3 testing becomes available, he would consider adding it to the biomarker assay, particularly at the time of diagnosis or recurrence.

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs trastuzumab emtansine in the context of HER2-positive breast cancer with brain metastases.

Mark R. Litzow, MD, discusses the findings from the ECOG-ACRIN E1910 trial which evaluated blinatumomab added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia.

Binod Dhakal, MD, MS, discusses the key takeaways from the CARTITUDE-4 trial which were presented at the 2024 International Myeloma Society Annual Meeting.

Ticiana Leal, MD, discusses how lurbinectedin, a synthetic alkaloid derived from marine sources, exerts its antitumor effects by binding to DNA and disrupting repair mechanisms, highlighting promising efficacy results in the Phase 2 PMO1183 trial, where it achieved a 45% objective response rate (ORR) and an 11.2-month median overall survival in patients with relapsed small cell lung cancer (SCLC).

Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab plus lazertinib vs osimertinib was presented at the European Society for Medical Oncology Congress 2024, shedding light on potential strategies for managing EGFR-mutated and MET-amplified non–small cell lung cancer.

Erika Hamilton, MD, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer.

Mark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair-deficient rectal cancer about the potential for long-term disease control with this agent.

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

Erika Hamilton, MD, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer.

Binod Dhakal, MD, MS, discusses how the efficacy results observed with ciltacabtagene autoleucel in the CARTITUDE-4 trial compare with other therapies that are used for the treatment of relapsed/refractory multiple myeloma.

Ariel Lopez-Chavez, MD, provides an overview of the most promising advancements in targeted therapies for the treatment of small cell lung cancer.

Stephen M. Ansell, MD, PhD, discusses how immunotherapy is being integrated into treatment for patients with advanced stage Hodgkin lymphoma.

Binod Dhakal, MD, MS, discusses the safety and efficacy findings from the CARTITUDE-4 trial.

Binod Dhakal, MD, MS, provides an overview of the CARTITUDE-4 trial, including its methods, design, and inclusion criteria.

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

Erika Hamilton, MD, discusses the different classes of endocrine therapies and how they compare to one another.

Joshua K. Sabari, MD, discusses the unique mechanism of action of B7-H3, highlighting its role as an immune checkpoint regulator that is overexpressed in SCLC and associated with poor prognosis. He notes that B7-H3 blockade can enhance CD8-positive T-cell activity and may serve as a promising treatment option for SCLC that has progressed after platinum-based chemotherapy.

Saeed Sadeghi, MD, shares his current approach to treating anemia in lower-risk myelodysplastic syndromes (LR-MDS), detailing when to choose erythropoiesis-stimulating agents (ESAs) for first-line treatment, conditions for switching therapies, and factors influencing the decision to use luspatercept as a first-line option, including considerations for dose escalation.

Yoshiaki Nakamura, MD, PhD, discusses the quantification threshold for tissue-free ctDNA in detecting residual tumor fractions, highlights additional mutations and hypermethylated loci identified by epigenomic assays, and examines how these assays complement current radiographic monitoring in stage II to III CRC while also considering their evolving role in identifying MRD to enhance recurrence-free survival.

Joshua K. Sabari, MD, discusses the anticipated clinical benefits of adding tarlatamab to durvalumab as maintenance therapy for patients with ES-SCLC, highlighting that statistically significant trial end points, such as improved PFS and OS, could encourage community oncologists to adopt this dual maintenance approach.

Mark R. Litzow, MD, discusses the methods and design used in the ECOG-ACRIN E1910 trial.

Jacob E. Berchuck, MD, discusses the potential of liquid biopsies to enhance clinical decision-making regarding PSMA-directed therapies.

Erika Hamilton, MD, discusses how novel endocrine therapies improve treatment for metastatic breast cancer.

Erika Hamilton, MD, discusses some of the most promising endocrine therapies in breast cancer.